Nintedanib is a multikinase inhibitor inhibiting the receptor tyrosine kinase of platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGFβ) [179], thus targeting several molecular pathways involved in the pathogenesis of IPF, such as fibroblast proliferation, migration and differentiation, and the secretion of ECM. The gene discussed is TGFB1; the disease is idiopathic pulmonary fibrosis.